---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-092830"
form_type: "8-K"
ticker: "JANX"
cik: "0001817713"
company_name: "Janux Therapeutics, Inc."
filed_at: "2024-08-07T23:59:59+00:00"
generated_at: "2026-05-31T11:51:56.677361+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Janux Q2 2024 net loss $6.0M; cash $646.3M; receives $7.5M Merck milestone

## Summary
- Net loss of $6.0M vs $17.5M in Q2 2023; improvement driven by $7.5M milestone payment from Merck.
- Cash and investments $646.3M at June 30, 2024, up from $344.0M at Dec 31, 2023.
- R&D expense flat at $14.9M; G&A expense $7.8M vs $6.9M in prior year.
- Enrollment ongoing for JANX007 (PSMA) and JANX008 (EGFR) trials; JANX007 data update expected 2H 2024.
- Appointed Eric Dobmeier and Natasha Hernday to Board of Directors.

## SEC filing metadata
- accession: 0000950170-24-092830
- form_type: 8-K
- ticker: JANX
- cik: 0001817713
- company_name: Janux Therapeutics, Inc.
- filed_at: 2024-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1817713/000095017024092830/0000950170-24-092830-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1817713/000095017024092830/janx-20240807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-092830
- JSON: https://secwatch.observer/filing/0000950170-24-092830.json
- Plain text: https://secwatch.observer/filing/0000950170-24-092830.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.